Korro Bio Doses First First Group Of Patients In Its Phase 1/2 Clinical Study Of KRRO-121 To Treat Hyperammonemia In Patients With Urea Cycle Disorders

Korro Bio, Inc. (Nasdaq: KRRO) has announced that it has dosed the first cohort of participants in its Phase 1/2 clinical trial for KRRO-121, an RNA-editing oligonucleotide aimed at treating hyperammonemia in patients with urea cycle disorders and hepatic encephalopathy. This development marks a significant step in the company's efforts to leverage its OPERA® platform for genetic medicines targeting rare diseases.